Neovacs Plunges 9.6% as Investors Question Its Biotech Valuation
Neovacs’ sharp drop from €0.70 to €0.11 shows the risk of biotech hype, revealing how unproven pipelines can crush investor confidence.
3 minutes to read
NEOVACS
Neovacs Shares Plunge to 52‑Week Low Amid Valuation and Liquidity Concerns
Neovacs shares fall to a 52‑week low as investors weigh valuation, liquidity and biotech competition, while its Kinoid vaccine pipeline may still spark future upside.
3 minutes to read
Neovacs Stock Plummets 23% – Market Cap Rises to €18.8 k Amid Low‑Price Volatility
Neovacs (ALNEV.PA) plummets 23% to €0.10, trading 24h volume €20.9k; biotech firm’s Kinoid vaccine pipeline targets autoimmune and cancer diseases.
2 minutes to read